Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

South Korea’s BiocurePharm To Produce Biosimilars In Thailand

This article was originally published in PharmAsia News

Executive Summary

SEOUL - South Korean biopharmaceutical company BiocurePharm signed a memorandum of understanding with Thailand pharmaceutical distributor Kwang Tiang Dispensary to build a $20 million plant in Thailand to produce five types of biosimilar products for anemia and hepatitis, BiocurePharma announced Nov. 13

You may also be interested in...



Venture Capitalist Sheds Light On Market, Funding Options – Bio Korea (Part 1 of 2)

OSONG, South Korea - Venture capitalists are seeing the biggest returns from technology platforms or single-project financing, Hui-Hsing Ma, venture partner with TVM Capital told Bio Korea attendees.

Asia Partnerships Critical To Big Pharma’s Drying Pipelines, Merck Exec Tells Bio Korea (Part 2 of 2)

[Editor's note: This is part two of a two-part story from Bio Korea; part one was published in PharmAsia News, Oct. 12, 2008.]

Fresh Concerns Over Biosimilar ESA Use In Thailand Raises Takeda’s Hematide Prospects

SHANGHAI - Fresh safety concerns could be raised over the use of biosimilar erythropoietin stimulating agents after a patient in Thailand, who received an epoetin alfa biosimilar, developed ESA-related pure red cell aplasia, according to Baird analyst Christopher Raymond

Related Content

UsernamePublicRestriction

Register

LL035386

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel